Reinsurance in China critical illness insurance — the international and domestic reinsurers providing risk capacity, actuarial expertise, and product development support enabling the enormous Chinese CI market — creates an important market infrastructure dimension, with the China Critical Illness Insurance Market reflecting reinsurance as a commercially significant market support mechanism.

International reinsurers' China CI role — the Munich Re, Swiss Re, Hannover Re, Gen Re, and RGA (Reinsurance Group of America) providing facultative and treaty reinsurance capacity, actuarial support, and global morbidity experience to Chinese CI insurers. International reinsurers' global CI morbidity databases enabling more accurate pricing for conditions where Chinese historical data is limited.

China Re's domestic reinsurance position — the state-owned China Reinsurance Group providing domestic reinsurance capacity, regulatory-aligned product actuarial support, and pool mechanisms for catastrophic CI risk — represents the domestic reinsurance anchor for Chinese CI market stability.

RGA's CI market leadership — the Reinsurance Group of America's particular strength in Chinese CI reinsurance from specialized CI actuarial expertise, global cancer incidence and treatment cost databases, and deep Chinese insurer relationships — creating RGA's distinctive market position. RGA's CI reinsurance expertise informing both risk assessment and product design for its Chinese life insurance company clients.

Do you think Chinese CI reinsurance capacity constraints could limit primary insurer CI volume growth, or is reinsurance capacity for this market segment adequate for foreseeable demand growth?

FAQ

Why do Chinese life insurers use reinsurance for CI? CI reinsurance rationale: risk concentration management (single insurer cannot absorb all CI claims in catastrophic epidemic); actuarial uncertainty (limited domestic morbidity data for some conditions); capital efficiency (reinsurance releasing capital enabling premium growth); product development support (reinsurer actuarial expertise for new product pricing); tail risk management (very old age, rare conditions); facultative reinsurance: individual large sum insured policies exceeding insurer retention; treaty reinsurance: quota share or surplus share arrangements on entire CI portfolio; international reinsurer value: global cancer incidence data, treatment cost trends, new medical technology impact assessment.

What role do international reinsurers play in China CI product development? International reinsurer contributions: Munich Re: global medical cost data, pandemic risk modeling, CI definition technical input; Swiss Re: sigma economic data, CI market research, longevity risk; RGA: specialized CI block expertise, disability and morbidity management, claims experience analysis; Hannover Re: competitive pricing support, regional CI market expertise; contributions: actuarial support for pricing new conditions; incidence rate data from international experience; product innovation ideas (multi-payment, income replacement CI); regulatory submission actuarial certification; risk appetite communication to Chinese insurance leadership; pricing technology tools.

#ChinaCriticalIllness #CIreinsurance #MunichReChina #SwissReChina #RGAchina #InsuranceReinsurance